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Background
During the process of T cell priming to peptide antigens,
the T cell receptor (TCR) undergoes gene rearrangements
that result in a peptide-binding region (complementarity
determining region, CDR) which can act as a unique
molecular fingerprint for similar T cell clonotypes. The
purpose of this study was to assess high-throughput TCR
DNA sequencing to analyze qualitative and quantitative
measures of human T cell clonotype expansions both in
vitro and in vivo.
Methods
Human lymph nodes derived from patients with mela-
noma (melanoma-draining lymph node cells, MDLN)
were culture-activated using either anti-CD3/CD28 beads
and IL-2 100 IU/ml alone or in combination with anti-
VEGF neutralizing antibody, for 14 days. The two resul-
tant MDLN cultures were compared for overall T cell
expansion, cell surface phenotype, intracellular cytokine
staining and high-throughput TCR DNA sequencing
(ImmunoSEQ, Adaptive Biotechnologies). In addition,
both TDLN cell cultures were injected intravenously into
SCID mice bearing A375 melanoma xenografts and bone
marrow was harvested to assess for persistence of trans-
ferred human melanoma MDLN cells.
Results
Overall T cell expansion and cell surface phenotype of
MDLN cell cultures was similar. MDLN cells cultured in
the presence of anti-VEGF neutralizing antibody demon-
strated higher baseline levels of intracellular interferon-g.
TCR sequencing analysis comparing day 0 versus day 14
cultured MDLN cells demonstrated approximately 10%
shared T cell clonotypes following culture activation with
anti-CD3/CD28 beads and IL-2. As a point of reference,
the proportion of shared T cell clonotypes between two
different patient MDLN cells was approximately 0.6%.
Addition of anti-VEGF antibody during culture of MDLN
cells resulted in common T cell clonotypes of approxi-
mately 1% (day 0 versus day 14), confirming the expansion
of molecularly distinct T cell clonotypes. Human MDLN
cells infused into SCID mice bearing A375 melanoma
xenografts demonstrated persistence of T cell clonotypes
in the bone marrow several weeks after infusion. It is
notable that none of the low frequency T cell clonotype
expansion differences between samples could be readily
identified using VDJ gene usage or CDR3 length analysis.
Conclusions
This study demonstrates that CDR3 sequence data that is
quantitative and recognizes low frequency T cell clono-
types is more sensitive than V gene usage and CDR3
length analysis. In addition, CDR3 sequencing may provide
utility in the qualitative assessment of T cells both in vitro
and in vivo.
Authors’ details
1Case Western Reserve University School of Medicine, Cleveland, OH, USA.
2Division of Surgical Oncology, University Hospitals Case Medical Center,
Cleveland, OH, USA.
Published: 6 November 2014
doi:10.1186/2051-1426-2-S3-P143
Cite this article as: Strohl et al.: Use of high throughput T cell receptor
(TCR) DNA sequencing to characterize T cell infusion products and
track clonal expansion in vivo. Journal for ImmunoTherapy of Cancer 2014
2(Suppl 3):P143.
1Case Western Reserve University School of Medicine, Cleveland, OH, USA
Full list of author information is available at the end of the article
Strohl et al. Journal for ImmunoTherapy of Cancer 2014, 2(Suppl 3):P143
http://www.immunotherapyofcancer.org/content/2/S3/P143
© 2014 Strohl et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
